Profile data is unavailable for this security.
About the company
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9-amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2) /neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. It has commenced a Phase III clinical trial, Flamingo-01, an immunotherapy to prevent breast cancer recurrences. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer.
- Revenue in USD (TTM)0.00
- Net income in USD-19.48m
- Incorporated2006
- Employees4.00
- LocationGreenwich Lifesciences Inc3992 Bluebonnet Dr, Building 14STAFFORD 77477United StatesUSA
- Phone+1 (203) 434-3290
- Fax+1 (302) 636-5454
- Websitehttps://greenwichlifesciences.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anavex Life Sciences Corp | 0.00 | -39.95m | 366.98m | 34.00 | -- | 2.90 | -- | -- | -0.4649 | -0.4649 | 0.00 | 1.37 | 0.00 | -- | -- | 0.00 | -31.08 | -33.08 | -33.63 | -36.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.85 | -- | -- | -- |
| Forte Biosciences Inc | 0.00 | -51.74m | 369.29m | 16.00 | -- | 4.39 | -- | -- | -4.49 | -4.49 | 0.00 | 6.71 | 0.00 | -- | -- | 0.00 | -89.96 | -64.69 | -110.72 | -71.52 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.71 | -- | -38.72 | -- |
| Climb Bio Inc | 0.00 | -50.75m | 375.01m | 17.00 | -- | 2.12 | -- | -- | -0.7507 | -0.7507 | 0.00 | 2.60 | 0.00 | -- | -- | 0.00 | -25.09 | -39.53 | -25.62 | -41.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -110.42 | -- | -- | -- |
| PepGen Inc | 0.00 | -93.56m | 378.80m | 81.00 | -- | 2.32 | -- | -- | -2.84 | -2.84 | 0.00 | 2.37 | 0.00 | -- | -- | 0.00 | -51.93 | -45.06 | -56.56 | -49.76 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -14.44 | -- | 76.52 | -- |
| Allogene Therapeutics Inc | 0.00 | -212.02m | 379.79m | 226.00 | -- | 1.20 | -- | -- | -0.981 | -0.981 | 0.00 | 1.41 | 0.00 | -- | -- | 0.00 | -41.21 | -31.11 | -43.96 | -33.14 | -- | -- | -- | -1,187.06 | -- | -- | 0.00 | -- | -76.84 | -- | 21.29 | -- | -57.62 | -- |
| Monopar Therapeutics Inc | 0.00 | -19.44m | 381.38m | 16.00 | -- | 2.69 | -- | -- | -3.44 | -3.44 | 0.00 | 21.25 | 0.00 | -- | -- | 0.00 | -25.88 | -52.66 | -26.53 | -59.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -85.50 | -- | -- | -- |
| Northwest Biotherapeutics Inc | 937.00k | -91.22m | 382.93m | 25.00 | -- | -- | -- | 408.68 | -0.0655 | -0.0655 | 0.0007 | -0.0627 | 0.0313 | -- | -- | 37,480.00 | -299.59 | -398.92 | -- | -- | -- | -- | -9,580.90 | -8,255.92 | -- | -6.69 | -- | -- | -28.47 | -10.53 | -32.34 | -- | 23.01 | -- |
| Greenwich Lifesciences Inc | 0.00 | -19.48m | 387.79m | 4.00 | -- | 176.71 | -- | -- | -1.46 | -1.46 | 0.00 | 0.1584 | 0.00 | -- | -- | 0.00 | -404.39 | -49.65 | -543.43 | -51.94 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.57 | -- | -- | -- |
| Bicycle Therapeutics PLC (ADR) | 28.34m | -250.66m | 390.54m | 305.00 | -- | 0.6309 | -- | 13.78 | -3.62 | -3.62 | 0.4094 | 8.92 | 0.0322 | -- | 0.4525 | 92,914.76 | -28.47 | -26.61 | -30.66 | -29.60 | -- | -- | -884.51 | -587.28 | -- | -- | 0.0015 | -- | 30.76 | 20.65 | 6.44 | -- | -4.50 | -- |
| Tectonic Therapeutic Inc | 0.00 | -67.30m | 393.98m | 51.00 | -- | 1.47 | -- | -- | -3.85 | -3.85 | 0.00 | 14.30 | 0.00 | -- | -- | 0.00 | -30.20 | -- | -32.12 | -- | -- | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | -35.40 | -- | -- | -- |
| NovaBridge Biosciences | 0.00 | -26.33m | 394.30m | 32.00 | -- | 1.52 | -- | -- | -0.3045 | -0.2827 | 0.00 | 2.25 | 0.00 | -- | -- | 0.00 | -10.32 | -26.21 | -10.92 | -30.19 | -- | -- | -- | -389.26 | -- | -- | 0.00 | -- | -100.00 | -- | 39.56 | -- | -51.41 | -- |
| Aclaris Therapeutics Inc | 15.74m | -141.68m | 395.46m | 64.00 | -- | 3.29 | -- | 25.12 | -1.38 | -1.38 | 0.136 | 1.11 | 0.088 | -- | 6.27 | 245,968.80 | -79.17 | -48.16 | -90.39 | -55.11 | 3.98 | 40.68 | -900.01 | -483.49 | -- | -- | 0.00 | -- | -40.09 | 34.67 | -49.26 | -- | 86.02 | -- |
| Benitec Biopharma Inc | 0.00 | -41.82m | 396.19m | 19.00 | -- | 3.28 | -- | -- | -1.18 | -1.18 | 0.00 | 3.57 | 0.00 | -- | -- | 0.00 | -50.76 | -79.73 | -52.87 | -88.81 | -- | 88.41 | -- | -53,777.78 | -- | -- | 0.00 | -- | -- | -- | -69.50 | -- | -28.30 | -- |
| Absci Corp | 2.82m | -114.60m | 396.98m | 156.00 | -- | 1.88 | -- | 141.02 | -0.903 | -0.903 | 0.022 | 1.40 | 0.0117 | -- | 2.25 | 18,044.87 | -47.73 | -37.10 | -54.08 | -41.33 | -- | -- | -4,071.19 | -1,697.47 | -- | -410.97 | 0.0065 | -- | -20.71 | 17.09 | 6.75 | -- | -18.12 | -- |
Data as of Feb 11 2026. Currency figures normalised to Greenwich Lifesciences Inc's reporting currency: US Dollar USD
8.08%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Sep 2025 | 329.40k | 2.38% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 250.42k | 1.81% |
| Geode Capital Management LLCas of 30 Sep 2025 | 142.12k | 1.03% |
| Carne Global Fund Managers (Schweiz) AGas of 31 Jan 2025 | 115.99k | 0.84% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 81.95k | 0.59% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2025 | 62.53k | 0.45% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 44.95k | 0.32% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 38.40k | 0.28% |
| Marshall Wace LLPas of 30 Sep 2025 | 32.05k | 0.23% |
| DWS Investments (UK) Ltd.as of 30 Sep 2025 | 21.50k | 0.16% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
